Retrospective Analysis of Vaccination Status and Predominant Viral Variants in Patients Hospitalized with COVID-19 in Reus, Spain.
COVID-19
SARS-CoV-2
breakthrough infection
pandemic
vaccination
vaccines
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
30 03 2023
30 03 2023
Historique:
received:
21
02
2023
revised:
20
03
2023
accepted:
28
03
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
SARS-CoV-2 infection in already-vaccinated individuals is still possible and may require hospitalization. The aim of the present study was to evaluate the clinical evolution of patients with COVID-19 admitted to a public hospital. The outcomes were assessed in relation to the predominant viral variant and the vaccination status. This retrospective study was performed on 1295 COVID-19-positive patients who attended a 352-bed university hospital between 2021 and 2022. Clinical variables and vaccination status were recorded. Of the patients, 799 had not been vaccinated (NV, 61.7%), 449 were partially vaccinated (PV, 34.7%), and 47 were completely vaccinated (CV, 3.6%). The mean age of the CV patients was significantly higher than that of PV and NV. Additionally, they had higher percentages of chronic diseases. The outcomes depended on age but not on vaccination status. There were 209 patients admitted during the Omicron-infection period, of whom 70 (33.5%) were NV, 135 (64.6%) were PV, and 4 (1.9%) were CV. In conclusion, correct vaccination greatly reduces the risk of acquiring severe COVID-19. Partial vaccination does not guarantee protection of the population. This highlights the need for continuous vaccination promotion with all recommended doses, while also investigating alternative treatments for those patients who do not respond to the vaccines.
Identifiants
pubmed: 37112865
pii: v15040886
doi: 10.3390/v15040886
pmc: PMC10143314
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):118-124
pubmed: 35085218
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1625-1630
pubmed: 36580424
MMWR Morb Mortal Wkly Rep. 2022 Jul 08;71(27):878-884
pubmed: 35797216
Arch Public Health. 2022 Sep 2;80(1):200
pubmed: 36050781
Viruses. 2022 Oct 17;14(10):
pubmed: 36298839
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
BMJ. 2022 Oct 11;379:e072065
pubmed: 36220174
Lancet Healthy Longev. 2022 Sep;3(9):e589-e598
pubmed: 35935474
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Clin Microbiol Infect. 2022 Dec;28(12):1629-1635
pubmed: 35779764
BMJ. 2021 Apr 16;373:n1000
pubmed: 33863709
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
Ann Intern Med. 1992 Dec 15;117(12):1003-9
pubmed: 1443968
Sci Rep. 2022 Oct 17;12(1):17384
pubmed: 36253391
Lancet Infect Dis. 2022 Jul;22(7):959-966
pubmed: 35468332
MMWR Morb Mortal Wkly Rep. 2022 Aug 26;71(34):1085-1091
pubmed: 36006841
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657
pubmed: 34245907
JAMA Intern Med. 2022 Oct 1;182(10):1071-1081
pubmed: 36074486
PLoS One. 2022 Jul 15;17(7):e0270485
pubmed: 35839210
J Investig Med. 2022 Aug;70(6):1429-1432
pubmed: 35768140
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428